Analysts Set Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) PT at $34.60

Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) have earned a consensus rating of “Buy” from the five analysts that are presently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $34.60.

Several brokerages recently commented on KNSA. Evercore ISI upped their target price on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Jefferies Financial Group began coverage on Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 target price on the stock. Finally, Wedbush upped their target price on Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an “outperform” rating in a research report on Tuesday, July 23rd.

Kiniksa Pharmaceuticals Stock Performance

Kiniksa Pharmaceuticals stock opened at $21.48 on Friday. The firm has a market cap of $1.53 billion, a price-to-earnings ratio of -156.70 and a beta of 0.35. Kiniksa Pharmaceuticals has a 52-week low of $14.12 and a 52-week high of $28.15. The firm has a 50 day moving average price of $25.40 and a two-hundred day moving average price of $22.53.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.17). The firm had revenue of $112.21 million during the quarter, compared to analyst estimates of $111.51 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. Kiniksa Pharmaceuticals’s quarterly revenue was up 67.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.20) EPS. As a group, equities research analysts predict that Kiniksa Pharmaceuticals will post -0.47 EPS for the current fiscal year.

Insider Buying and Selling

In related news, COO Eben Tessari sold 17,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total transaction of $456,790.00. Following the transaction, the chief operating officer now directly owns 109,975 shares of the company’s stock, valued at approximately $2,955,028.25. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, COO Eben Tessari sold 17,000 shares of the stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total value of $456,790.00. Following the completion of the sale, the chief operating officer now directly owns 109,975 shares of the company’s stock, valued at $2,955,028.25. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider John F. Paolini sold 60,692 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total value of $1,585,275.04. Following the completion of the sale, the insider now directly owns 52,038 shares of the company’s stock, valued at approximately $1,359,232.56. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 112,692 shares of company stock valued at $2,950,315. 54.57% of the stock is owned by company insiders.

Institutional Trading of Kiniksa Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of KNSA. CWM LLC raised its stake in shares of Kiniksa Pharmaceuticals by 443.0% in the third quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $61,000 after purchasing an additional 1,998 shares during the last quarter. Lazard Asset Management LLC purchased a new position in shares of Kiniksa Pharmaceuticals in the 1st quarter worth approximately $71,000. nVerses Capital LLC bought a new position in shares of Kiniksa Pharmaceuticals in the third quarter valued at approximately $80,000. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Kiniksa Pharmaceuticals during the second quarter valued at approximately $100,000. Finally, Lynx1 Capital Management LP purchased a new stake in shares of Kiniksa Pharmaceuticals during the second quarter valued at approximately $177,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.